Replies to post #124465 on Biotech Values

[DewDiligence]

Please show us an instance where a biotech company has voluntarily laid off manufacturing staff to resolve a short-term issue that had nothing to do with end-user demand for the company’s products. I don’t think it’s ever happened.

Skilled biotech-manufacturing personnel are not a dime a dozen. It would be colossally wasteful to fire such people and then have to train replacements a short time later.

[DewDiligence]

DNDN ($4.95), -20% on layoff, permanent plant closure in NJ, and generally awful outlook.

Does anyone here still think the problem with Provenge is merely slow reimbursement (what management inventively called “low cash density”)?